TriNetX Live™

by TriNetX  · Based in United States → — The Global Truth Engine for Better Human Health™
oncology-ai
Website Demo Contact
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

TriNetX Live™ is a leading global health research network and real-world data platform designed for healthcare organizations, pharmaceutical companies, and their researchers. It empowers physicians and scientists to efficiently design clinical trial protocols, precisely identify patient cohorts based on real-world data, and match patients to relevant clinical trials, accelerating the path to new therapies and improved health outcomes.

The platform operates as a “Global Truth Engine,” combining trusted, directly-sourced data with a powerful fusion of AI and human intelligence to deliver answers that withstand rigorous scrutiny. TriNetX connects healthcare organizations and researchers worldwide, providing a clear view of real patient populations without relying on simulations or guesses. It is recognized as one of the world’s most-cited data sources in peer-reviewed journals, ensuring scientific confidence in its insights.

For healthcare providers, TriNetX Live™ offers a crucial advantage by expanding their view beyond internal data. It provides access to global real-world intelligence, enabling them to identify high-value services with precision, engineer high-performance networks, and contribute to groundbreaking research. The platform harmonizes diverse data sources and leverages machine learning to uncover patterns, accelerate research, and generate real-world evidence in near-real-time.

TriNetX maintains relentless integrity by keeping identifiable data securely within its more than 11,000+ clinical sites across 20+ countries, preserving security, provenance, and granularity. This commitment, combined with high-touch partnerships and hands-on customer support, ensures that teams can ask smarter questions, pinpoint the right data, interpret results, and unearth actionable insights effectively.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Global Real-World Data Network
  • AI and Human Intelligence Fusion
  • Real-time Iterative Querying
  • Patient Cohort Identification
  • Clinical Trial Design
  • Real-World Evidence Generation
  • Secure Data Governance
  • High-Touch Customer Support

Use Cases

  • Designing clinical trial protocols
  • Identifying specific patient cohorts
  • Matching patients to clinical trials
  • Generating real-world evidence for regulators
  • Understanding therapy performance in real-world settings
  • Improving health outcomes and research publication

What Physicians Need to Know

Clinical Trial Matching
TriNetX Liveu2122 optimizes clinical trial design and accelerates patient recruitment by leveraging real-time electronic health record (EHR) data from a global federated network of over 280 million patients across 21+ countries. It enables researchers to build and analyze patient cohorts, refine inclusion/exclusion criteria, and predict patient arrival rates for studies. The platform also facilitates the identification of optimal study sites and allows for direct engagement with healthcare providers for patient re-identification and enrollment.
Real-World Evidence Analysis
A core strength of TriNetX Liveu2122 is its robust real-world evidence (RWE) generation capabilities. The platform provides access to continuously refreshed, de-identified patient records, allowing users to analyze and compare outcomes, reveal treatment pathways, and uncover incidence and prevalence. It supports regulatory and clinical decision-making, disease research, and health economics and outcomes research (HEOR) by providing comprehensive analyses of disease prevalence, treatment patterns, and market dynamics.
Genomic Data Integration
TriNetX has enhanced its genomics data management and analytics through the acquisition of Zetta Genomics, enabling federated capture of multiomic data. The platform supports the integration of genomic profiles with phenotypic data (demographics, diagnoses, medications, lab results) to facilitate advanced pharmacogenomic and personalized medicine studies.
Literature Mining (Clinical Documents)
TriNetX offers a Natural Language Processing (NLP) service that extracts clinical facts from unstructured data within physician notes and clinical reports. This extracted data is then mapped to standardized clinical terminologies, making it available for analysis to enhance study feasibility, protocol design, and patient identification.
Target Identification Support
While not a primary molecule screening tool, TriNetX Liveu2122 supports target identification indirectly through the integration and analysis of genomic and phenotypic data, which can suggest avenues for determining disease mechanisms and potential treatment strategies. Additionally, AI models are being developed for disease prediction, which can inform the identification of therapeutic targets.
Safety Signal Detection
Through its EVIDEXu00ae pharmacovigilance platform, integrated with the TriNetX global network, TriNetX Liveu2122 provides comprehensive capabilities for effective detection, analysis, and management of safety signals. It supports active surveillance, automated signal detection, refinement, and trend analysis across various harmonized data sources, including spontaneous reporting systems and real-world data.
Collaboration Features
TriNetX Liveu2122 functions as a global health research network, fostering collaboration among healthcare organizations, pharmaceutical companies, and Contract Research Organizations (CROs). It supports multi-site research initiatives, enables healthcare organizations to re-identify patients for studies, and streamlines communication between sponsors and potential trial sites.
Publication Support
TriNetX provides guidelines and support for researchers utilizing its data for publications. It has become a highly cited real-world data source in peer-reviewed research, with a significant increase in citations annually, demonstrating its growing impact on scientific dissemination.
Physician Tip

Physicians can leverage TriNetX Liveu2122 to quickly assess the feasibility of research studies by querying large, de-identified patient cohorts in real-time, without requiring prior Institutional Review Board (IRB) approval for initial cohort discovery. This allows for rapid investigation of patient attributes, comorbidities, and the impact of various inclusion/exclusion criteria. The platform also enables physicians to identify potential trial candidates within their own patient populations for re-identification and recruitment into clinical studies, thereby accelerating patient access to innovative therapies. Furthermore, the ability to analyze real-world outcomes and treatment patterns can inform clinical decision-making and contribute to evidence-based practice.

TriNetX Liveu2122 integrates with various data sources, primarily electronic health records (EHRs) from a global network of healthcare organizations. It also links with claims data, mortality information, and other third-party datasets to provide a comprehensive patient view. The platform supports the integration of multiomic data, including genomic profiles, using FHIR standards. For pharmacovigilance, it integrates with internal ICSR databases, FAERS, VigiBase, EVDAS, and ClinicalTrials.gov. Future enhancements include enhanced API capabilities for partners to send study queries from their existing systems and conversational AI interfaces for natural language querying.

Details

Category Drug Discovery & Research, Population Health Analytics
Pricing Unknown — unknown
Free Trial No
DeploymentCloud
Mobile AppNo
API Available Yes
Data Export Yes
LanguagesEnglish
Training Yes
Target Sizelarge enterprises, academic institutions
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status No AI-estimated — unknown
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Oncology Ai

Social Proof

Customers15 of top 20 global pharma firms, 200+ healthcare organizations

Support & Reliability

Training Provided Yes

What the Web Says

TriNetX Liveu2122 is generally well-regarded by physicians and healthcare IT professionals for its ability to provide real-time access to de-identified patient data, significantly accelerating clinical trial feasibility and patient recruitment. Reviewers highlight its user-friendly interface and powerful analytics capabilities, though some note a learning curve for new users.

Overall: Positive

Strengths

  • Real-time access to de-identified patient data for research
  • Accelerates clinical trial feasibility and patient recruitment
  • User-friendly interface for data exploration
  • Powerful analytics and cohort building tools
  • Facilitates collaboration between researchers and sites
  • Improves efficiency in study design and execution

Limitations

  • Initial learning curve for new users
  • Data availability can vary by institution
  • Cost can be a barrier for smaller organizations
  • Reliance on data quality from contributing institutions
  • Some users desire more advanced customization options
  • Limited public discussion on platforms like Reddit or G2 specifically for 'Live' product

Based on reviews from: TriNetX.com (product information), Healthcare IT News (articles/interviews), Clinical Trials Arena (articles/interviews), Industry white papers and case studies, LinkedIn discussions (professional opinions), Academic research papers citing TriNetX

Last updated: 2026-08-25

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate TriNetX Live™

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

TriNetX
TriNetX LIVEu2122 Network Surpasses 300 Million Patients, Expanding Decision-Grade Evidence Across Global Healthcare
The TriNetX LIVEu2122 network has grown to over 300 million patients from 240+ healthcare organizations and 13,000+ sites worldwide, providing pharmaceutical companies, academic researchers, and healthcare providers with access to trusted, current, and clinically rich real-world data. This milestone reflects accelerating international growth and expands the decision-grade evidence available for improving patient care.
2026-06
TriNetX
TriNetX Appoints August Calhoun Chief Executive Officer
TriNetX, a leading federated health data network, announced the appointment of August Calhoun as Chief Executive Officer, effective immediately. Calhoun brings over 25 years of leadership experience in healthcare data, technology, and services.
2026-07
TriNetX
TriNetX Supports European Healthcare Organizations on the Path to EHDS Readiness
TriNetX is supporting European healthcare organizations in achieving EHDS readiness by enabling interoperability and compliance through its federated real-world data network. This initiative aims to unlock innovation and streamline data exchange within the European Health Data Space.
2026-08
TriNetX
Proof in Publications u2013 The Most Cited. The Most Trusted. TriNetX Real-World Data
As of July 2026, over 4,000 peer-reviewed publications have used or cited TriNetX data, with 738 publications appearing in Q2 2026 alone, marking a new quarterly record. This demonstrates the global research community's trust in the TriNetX network as a foundation for credible science.
2026-08
PR Newswire
TriNetX Unveils Conversational AI Interface and Enhanced API Capabilities
TriNetX announced new AI capabilities, including a conversational AI interface, that allow researchers to query its global network using natural language, aiming to democratize clinical research analytics and reduce roadblocks between researchers and insights. The platform has already shown success in reducing protocol amendments and improving site identification efficiency.
2026-01
TriNetX
TriNetX Named Among the Top 25 Healthcare Software Companies of 2025
TriNetX was recognized by The Healthcare Technology Report as one of the Top 25 Healthcare Software Companies of 2025 for its innovation in real-world data, artificial intelligence, and clinical research transformation. The company's TriNetX LIVEu2122 platform integrates de-identified patient data from over 300 million patients globally.
2025-09
PR Newswire
TriNetX Becomes the Most Cited Real-World Data Source in Peer-Reviewed Research
TriNetX has become the most cited electronic health record dataset in peer-reviewed publications, with over 2,000 citations and nearly 80% year-over-year growth. This highlights the increasing use of TriNetX data by clinical researchers, public health agencies, and healthcare organizations worldwide.
2025-10
TriNetX
Penn State Joins TriNetX Research Network
Penn State has joined the TriNetX Research Network, gaining access to large datasets to enhance its ability to apply for grants and publish research papers. This partnership allows Penn State researchers to query approximately 1.5 million patient records on the TriNetX platform, facilitating broader and more diverse research.
unknown

Videos

Product demos, reviews, and walkthroughs for TriNetX Live™.

View all on YouTube

Frequently Asked Questions

TriNetX Liveu2122 allows you to query a vast network of de-identified patient data from electronic health records globally to identify specific patient cohorts for your research. This enables you to assess the feasibility of your study protocols, refine inclusion/exclusion criteria, and design more efficient clinical trials.
TriNetX Liveu2122 operates with de-identified patient data and is certified to ISO 27001:2022, adhering to HIPAA and GDPR regulations to ensure patient privacy and data security. Generally, IRB approval is not required for analyses conducted within the platform or for downloading data from the Research Network, as the data is de-identified.
Yes, a key limitation is that the data primarily originates from insured populations within academic and acute care settings, which might not fully represent broader demographic groups and could affect the generalizability of your findings. Additionally, the platform's reliance on retrospective data from electronic health records can introduce biases, and the accuracy of EHR coding is a critical factor in data reliability.
For healthcare organizations contributing data, participation in the TriNetX network often incurs no direct financial cost, and they gain access to the platform's query and analytic capabilities. However, custom queries or specific data requests, especially for grant-funded projects, may involve fees, with some institutions charging around $180 per hour for custom queries.
Several other platforms offer real-world data and analytics for drug discovery research, including IQVIA, Truveta, and Atropos Health. Other notable healthcare data platforms that cater to biopharma workflows include Lifebit and Veeva Systems.
The data within TriNetX Liveu2122 is continuously updated, with many contributing healthcare organizations refreshing their data monthly, providing real-time insights. This agility allows researchers to react quickly to emerging health issues and novel therapies, which is crucial for timely drug discovery and development.
Yes, TriNetX Liveu2122 is designed to optimize clinical trial operations by helping researchers identify suitable sites with eligible patient populations and predict patient arrival rates. The platform facilitates connecting with healthcare providers at these sites for potential patient recruitment, significantly reducing the time for site identification.

Related Tools

MyTrials.ai
MyTrials.ai
Drug Discovery & Research
MyTrials.ai is an AI-powered platform for clinical trial recruitment, combining a verified patient network, intelligent matching, and human navigators to accelerate enrollment.
HypeCheck
2 Minute Medicine
Clinical Decision Support & Reference
HypeCheck™ instantly evaluates health articles, wellness advice, and viral trends by cross-referencing them directly against peer-reviewed literature on PubMed, active clinical trials, and official health agency guidance.
$4.99/month or $49.90/year
Scite
Scite
Drug Discovery & Research
Scite is an AI research tool that shows how papers have been cited, providing context on whether findings are supported or contradicted by subsequent research, which is valuable for medical writers and researchers.
Tiered pricing model with free, basic, premium, premium+, group, and enterprise plans.
Google Bard
Google
Clinical Decision Support & Reference
Google Bard, now known as Gemini, is a generative AI model that can assist healthcare professionals with tasks such as summarizing medical records and research papers, generating hypotheses, and providing information on medical conditions.
Freemium
AIDDISON Explorer
Sigma-Aldrich (Merck KGaA)
Drug Discovery & Research
AIDDISSON Explorer is an AI-powered drug discovery platform combining generative AI with computer-aided drug design for molecular generation, virtual screening, ADMET prediction, and retrosynthesis planning.
Noodle Biomedical Literature Discovery
Helena Bioinformatics
Drug Discovery & Research
Noodle is a biomedical literature discovery platform that allows researchers to search publications by meaning, inspect paper details, and explore related evidence through citation connections and semantic neighborhoods. It offers a public read-only Model Context Protocol (MCP) interface for AI agents.
Free

See all Drug Discovery & Research tools →

Suggest an Edit → | Last Verified: 2026-05-21 | First Added: 2026-05-21

Investors who backed TriNetX Live™

Funded through the company that built this tool.

Merck Global Health Innovation Fund
Corporate VC T3
Rahway, United States
$5M-$25M
Merck Global Health Innovation Fund is the dedicated corporate venture arm of Merck and Co (MSD), one of the most established and…
AI/ML in Healthcare Diagnostics
Merck
Corporate VC T3
Rahway, United States
$1M-$5M
Merck operates a complex set of corporate venture and strategic capital vehicles, including Merck Global Health Innovation Fund and the company’s broader…
AI/ML in Healthcare Diagnostics
AI Tool Finder
AI-powered search. Results may not be comprehensive.